Inter-laboratory assessment of a prototype multiplex kit for determination of recent HIV-1 infection

• Published in: PloS one Vol. 8; no. 10; p. e77765
• Main Authors: Curtis, Kelly A, Longosz, Andrew F, Kennedy, M Susan, Keating, Sheila, Heitman, John, Laeyendecker, Oliver, Owen, S Michele
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 17.10.2013; Public Library of Science (PLoS)
• Subjects: Acquired immune deficiency syndrome; Aerospace technology transfer; AIDS; Algorithms; Analytical chemistry; Assaying; Avidity; Coefficient of variation; Comparative analysis; Cross-Sectional Studies; Diagnosis; Disease prevention; Feasibility studies; Fluorescence; Glycoprotein gp120; Glycoprotein gp160; Health aspects; HIV; HIV antibodies; HIV Antibodies - immunology; HIV Infections - immunology; Human immunodeficiency virus; Humans; Immunoassay; Incidence; Infections; Laboratories; Multiplexing; Reactivity; Reproducibility; Seroconversion; Technology transfer; Atlanta Georgia; San Francisco California; United States > US; Georgia; California; Maryland; Baltimore Maryland
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0077765

Accurate and reliable laboratory-based assays are needed for estimating HIV-1 incidence from cross-sectional samples. We recently described the development of a customized, HIV-1-specific Bio-Plex assay that allows for the measurement of HIV-specific antibody levels and avidity to multiple analytes for improved HIV-1 incidence estimates. To assess intra- and inter-laboratory assay performance, prototype multiplex kits were developed and evaluated by three distinct laboratories. Longitudinal seroconversion specimens were tested in parallel by each laboratory and kit performance was compared to that of an in-house assay. Additionally, the ability of the kit to distinguish recent from long-term HIV-1 infection, as compared to the in-house assay, was determined by comparing the reactivity of known recent (infected <6 months) and long-term (infected >12 months) drug naïve specimens. Although the range of reactivity for each analyte varied between the prototype kit and in-house assay, a measurable distinction in reactivity between recent and long-term specimens was observed with both assays in all three laboratories. Additionally, kit performance was consistent between all three laboratories. The intra-assay coefficient of variation (CV), between sample replicates for all laboratories, ranged from 0.5% to 6.1%. The inter-laboratory CVs ranged from 8.5% to 21.3% for gp160-avidity index (a) and gp120-normalized mean fluorescent intensity (MFI) value (n), respectively. We demonstrate the feasibility of producing a multiplex kit for measuring HIV antibody levels and avidity, with the potential for improved incidence estimates based on multi-analyte algorithms. The availability of a commercial kit will facilitate the transfer of technology among diverse laboratories for widespread assay use.